| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ruixue Yuan, Yaojing Li, Xiangyi Li, Yingmei Fu, Ailing Ning, Dongxiang Wang, Ran Zhang, Shunying Yu, Qingqing X. Transcriptome analysis to explore the mechanism of downregulated TNIK influencing the effect of risperidone. Frontiers in pharmacology. vol 15. 2024-09-14. PMID:39268461. |
risperidone is one of the most reliable and effective antipsychotics for schizophrenia treatment. |
2024-09-14 |
2024-09-16 |
Not clear |
| Jianjun Weng, Xiaoli Zhu, Yu Ouyang, Yanqing Liu, Hongmei Lu, Jiakui Yao, Bo Pa. Identification of Immune-Related Biomarkers of Schizophrenia in the Central Nervous System Using Bioinformatic Methods and Machine Learning Algorithms. Molecular neurobiology. 2024-09-07. PMID:39243324. |
lastly, in a schizophrenia rat model, the eif4a2 expression levels were reduced in the model rat brains in a brain-regional dependent manner, but can be reversed by risperidone. |
2024-09-07 |
2024-09-10 |
human |
| Rawand M Daghmash, Mai S Khanfar, Ruba S Darwees. Risperidone Pellets, Pycnogenol Pharmaceutics. vol 16. issue 8. 2024-08-29. PMID:39204407. |
risperidone is an atypical antipsychotic medication used to treat schizophrenia and autism-related irritability. |
2024-08-29 |
2024-09-04 |
Not clear |
| Ai Goto, Ryuichi Kambayashi, Hiroko Izumi-Nakaseko, Yoshinori Takei, Atsushi Sugiyam. β-Adrenoceptor blockade can augment the torsadogenic action of risperidone. Journal of pharmacological sciences. vol 156. issue 2. 2024-08-23. PMID:39179332. |
risperidone is a second-generation antipsychotic for treating schizophrenia and bipolar disorder. |
2024-08-23 |
2024-08-27 |
Not clear |
| Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah, Bahar Beigi, Atefeh Motamedi-Manesh, Sogand Adibian, Salar Vasegh. Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine. Journal of psychiatric research. vol 178. 2024-08-15. PMID:39146821. |
on the other hand, risperidone is a potent antipsychotic medication that is approved for the treatment of schizophrenia and bipolar disorder. |
2024-08-15 |
2024-08-18 |
rat |
| Qi He, Peixin Zhu, Xiyan Liu, Chunyue Hu. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophrenia research. vol 271. 2024-08-07. PMID:39111258. |
association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: a systematic review and meta-analysis. |
2024-08-07 |
2024-08-10 |
Not clear |
| Surachai Ngamratanapaiboon, Napatarin Srikornvit, Patipol Hongthawonsiri, Krittaboon Pornchokchai, Siriphattarinya Wongpitoonmanachai, Jiajun Mo, Petchlada Pholkla, Pracha Yambangyang, Phichanan Duchda, Jenyuk Lohwacharin, Watcharaporn Devakul Na Ayutthay. Elucidating of the metabolic impact of risperidone on brain microvascular endothelial cells using untargeted metabolomics-based LC-MS. Toxicology reports. vol 13. 2024-08-06. PMID:39104367. |
elucidating of the metabolic impact of risperidone on brain microvascular endothelial cells using untargeted metabolomics-based lc-ms. risperidone is useful for the treatment of schizophrenia symptoms; however, it also has side effects, and an overdose can be harmful. |
2024-08-06 |
2024-08-08 |
human |
| David Bibi, Raphael Bilgraer, Lilach Steiner, Hussein Halla. Physiologically-Based Pharmacokinetic Modeling and In Vitro-In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human. Pharmaceutics. vol 16. issue 7. 2024-07-27. PMID:39065593. |
tv-46000 (uzedy, teva) is a long-acting subcutaneous (sc) injectable formulation of risperidone, approved for the treatment of schizophrenia in adults. |
2024-07-27 |
2024-07-29 |
human |
| Wonsuk Shin, Dong Hyeon Lee, Hyounggyoon Yoo, Huiyoung Jung, Minji Bang, Anhye Ki. Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse. Pharmaceuticals (Basel, Switzerland). vol 17. issue 7. 2024-07-27. PMID:39065735. |
assessing the clinical efficacy of therapeutic drug monitoring for risperidone and paliperidone in patients with schizophrenia: insights from a clinical data warehouse. |
2024-07-27 |
2024-07-29 |
Not clear |
| Wonsuk Shin, Dong Hyeon Lee, Hyounggyoon Yoo, Huiyoung Jung, Minji Bang, Anhye Ki. Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse. Pharmaceuticals (Basel, Switzerland). vol 17. issue 7. 2024-07-27. PMID:39065735. |
our study cohort comprised patients diagnosed with schizophrenia undergoing treatment with either risperidone or paliperidone. |
2024-07-27 |
2024-07-29 |
Not clear |
| Justin Faden, Camila Ramirez, Vanessa Martinez, Leslie Citrom. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder. Expert review of neurotherapeutics. 2024-07-24. PMID:39044342. |
an overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder. |
2024-07-24 |
2024-07-26 |
Not clear |
| John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart, Helena Knebel, Nir Sharon, Mark Suett, Kelli R Franzenburg, Glen L Davis, Christoph U Correl. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS drugs. 2024-07-02. PMID:38954317. |
tv-46000 is a long-acting subcutaneous antipsychotic (lasca) formulation of risperidone that is approved by the united states food and drug administration for the treatment of schizophrenia in adults. |
2024-07-02 |
2024-07-06 |
Not clear |
| Anton Freibüchler, Roland Seifer. Analysis of clinical studies on clozapine from 2012-2022. Naunyn-Schmiedeberg's archives of pharmacology. 2024-06-25. PMID:38918233. |
ziprasidone and risperidone can also be used well for the treatment of schizophrenia. |
2024-06-25 |
2024-06-29 |
Not clear |
| Rand Ghanma, Yara A Naser, Qonita Kurnia Anjani, Akmal Hidayat Bin Sabri, Aaron R J Hutton, Lalitkumar K Vora, Achmad Himawan, Natalia Moreno-Castellanos, Brett Greer, Helen O McCarthy, Alejandro J Paredes, Ryan F Donnell. Dissolving microarray patches for transdermal delivery of risperidone for schizophrenia management. International journal of pharmaceutics. 2024-06-16. PMID:38880253. |
dissolving microarray patches for transdermal delivery of risperidone for schizophrenia management. |
2024-06-16 |
2024-06-19 |
rat |
| Rand Ghanma, Yara A Naser, Qonita Kurnia Anjani, Akmal Hidayat Bin Sabri, Aaron R J Hutton, Lalitkumar K Vora, Achmad Himawan, Natalia Moreno-Castellanos, Brett Greer, Helen O McCarthy, Alejandro J Paredes, Ryan F Donnell. Dissolving microarray patches for transdermal delivery of risperidone for schizophrenia management. International journal of pharmaceutics. 2024-06-16. PMID:38880253. |
risperidone (ris) is a common drug prescribed for the treatment of schizophrenia. |
2024-06-16 |
2024-06-19 |
rat |
| Risako Fujikawa, Jun Yamada, Shoichiro Maeda, Kyoko M Iinuma, Genki Moriyama, Shozo Jinn. Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia. Journal of neurochemistry. 2024-05-21. PMID:38770640. |
inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia. |
2024-05-21 |
2024-05-27 |
mouse |
| Risako Fujikawa, Jun Yamada, Shoichiro Maeda, Kyoko M Iinuma, Genki Moriyama, Shozo Jinn. Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia. Journal of neurochemistry. 2024-05-21. PMID:38770640. |
in our study, we explored how the second-generation antipsychotic risperidone (ris) affects ros regulation and microglial activation in the hippocampus using a mouse ketamine (ket) model of schizophrenia. |
2024-05-21 |
2024-05-27 |
mouse |
| Zhiwei Huang, Lei Zhang, Yan Li, Yimin Yu, Yifeng Shen, Xiujia Sun, Kun Lou, Hongmei Luo, Zhibin Meng, Huafang Li, Yumei We. Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399363. |
population pharmacodynamic models of risperidone on panss total scores and prolactin levels in schizophrenia. |
2024-02-24 |
2024-02-26 |
Not clear |
| Zhiwei Huang, Lei Zhang, Yan Li, Yimin Yu, Yifeng Shen, Xiujia Sun, Kun Lou, Hongmei Luo, Zhibin Meng, Huafang Li, Yumei We. Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399363. |
this study aims to analyze the dynamic alterations in panss total scores and prolactin levels in patients with schizophrenia treated with risperidone, along with the influencing covariates. |
2024-02-24 |
2024-02-26 |
Not clear |
| Samantha Alvarez-Herrera, Mauricio Rosel Vales, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Yvonne Flores-Medina, José Luis Maldonado-García, Ricardo Saracco-Alvarez, Raúl Escamilla, Lenin Pavó. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399382. |
risperidone decreases expression of serotonin receptor-2a (5-ht2a) and serotonin transporter (sert) but not dopamine receptors and dopamine transporter (dat) in pbmcs from patients with schizophrenia. |
2024-02-24 |
2024-02-26 |
Not clear |